Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Psychiatry. Apr 19, 2026; 16(4): 114462
Published online Apr 19, 2026. doi: 10.5498/wjp.v16.i4.114462
Published online Apr 19, 2026. doi: 10.5498/wjp.v16.i4.114462
Serum 5-hydroxytryptamine levels as biomarkers for motor dysfunction and depression in Parkinson’s disease patients
Yu-Sheng Chen, Ke-Yi Lu, Ming Li, Tian Liu, Hai-Long Lu, Kun Hu, Department of Geriatrics, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China
Si-Yuan Yang, Department of Neurology, The First People’s Hospital of Xuzhou, Xuzhou 221002, Jiangsu Province, China
Shi-Guang Zhu, Department of Neurology, The Affiliated Xuzhou Municipal Hospital of Xuzhou Medical University, Xuzhou 221000, Jiangsu Province, China
Co-first authors: Yu-Sheng Chen and Si-Yuan Yang.
Co-corresponding authors: Hai-Long Lu and Kun Hu.
Author contributions: Chen YS and Yang SY contributed to study design, statistical analysis, manuscript writing, and they contributed equally to this manuscript and are co-first authors; Chen YS, Yang SY, Lu KY, Li M, and Liu T contributed to data collection; Lu KY, Li M, and Liu T contributed to patient recruitment, clinical assessment; Zhu SG contributed to clinical evaluation and resources; Lu HL and Hu K contributed to study supervision, funding acquisition, manuscript revision, and they contributed equally to this manuscript and are co-corresponding authors. All authors approved the final manuscript.
Supported by Jiangsu Provincial Geriatric Health Scientific Research Project, No. LKM2024016.
Institutional review board statement: This study was approved by the Ethics Committee of the Affiliated Hospital of Xuzhou Medical University (Approval No. XYFY2019-KL109-01). All research procedures complied with institutional guidelines and the principles of the Declaration of Helsinki.
Informed consent statement: All study participants, or their legal guardian, provided informed written consent prior to study enrollment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
STROBE statement: The authors have read the STROBE Statement-checklist of items, and the manuscript was prepared and revised according to the STROBE Statement-checklist of items.
Data sharing statement: No additional data are available.
Corresponding author: Kun Hu, MD, PhD, Department of Geriatrics, The Affiliated Hospital of Xuzhou Medical University, No. 99 Huaihai West Road, Xuzhou 221000, Jiangsu Province, China. xyhk4122@163.com
Received: October 17, 2025
Revised: November 23, 2025
Accepted: January 4, 2026
Published online: April 19, 2026
Processing time: 163 Days and 19.4 Hours
Revised: November 23, 2025
Accepted: January 4, 2026
Published online: April 19, 2026
Processing time: 163 Days and 19.4 Hours
Core Tip
Core Tip: This study investigated the role of serum serotonin [5-hydroxytryptamine (5-HT)] as a biomarker for complications in Parkinson’s disease (PD). We found that reduced serum 5-HT levels were independently associated with both levodopa-induced dyskinesia and depression, two common motor and non-motor complications of PD. Serum 5-HT showed good discriminative ability for identifying at-risk patients and may provide a simple peripheral marker for early risk stratification and personalized management in PD.